**Executive Summary**
Scientists at the Agharkar Research Institute (ARI), Pune, have developed an innovative biodegradable nanocarrier platform for targeted gene therapy in breast cancer. This next-generation nanomedicine uses a dual gene-silencing strategy to inhibit tumor growth while minimizing systemic toxicity, as reported on June 3, 2026. The research, published in *Advanced Healthcare Materials*, offers a promising framework for safer, precision-based alternatives to traditional chemotherapy.
**Key Points / Main Content**
**Advanced Nanocarrier Engineering**
* The system uses biodegradable mesoporous silica nanoparticles (MSNs) characterized by high loading capacity and tunable surface chemistry.
* The nanocarrier is functionalized with a protamine biopolymer and an MUC1-specific aptamer for precise tumor targeting.
* By targeting MUC1 receptors overexpressed on breast cancer cells, the system enhances cellular uptake and reduces off-target effects common in conventional therapies.
**Dual Gene-Silencing Strategy**
* The platform simultaneously delivers small interfering RNA (siRNA) molecules to silence two critical anti-apoptotic genes: MCL-1 and Survivin.
* These genes are known to promote tumor survival and drive resistance to standard therapies.
* A glutathione-responsive design triggers the controlled release of the therapeutic payload only after it enters the tumor microenvironment.
**Experimental Outcomes and Safety**
* Biological evaluations in MCF-7 breast cancer models showed robust gene knockdown, increased cell death (apoptosis), and substantial tumor inhibition.
* *In vivo* studies using SCID mice confirmed that the nanocarrier accumulates effectively at tumor sites.
* Histological assessments demonstrated minimal systemic toxicity, suggesting a safer profile than traditional chemotherapy.
**Impact Analysis**
**Cancer Researchers and Scientists**
**Impact**
The study provides a new framework for advancing precision oncology through the convergence of targeted delivery, stimuli-responsive release, and combinatorial gene silencing.
**Action Required**
Researchers should review the methodology published in *Advanced Healthcare Materials* to explore applications of this RNAi-based platform in other cancer models.
**Healthcare Providers and Oncologists**
**Impact**
The development offers a potential next-generation therapeutic strategy that addresses the limitations of systemic toxicity and therapy resistance in breast cancer.
**Action Required**
Clinical stakeholders should monitor the progression of this nanomedicine from laboratory and animal models toward potential clinical trials.
**Department of Science and Technology (DST), Government of India**
**Impact**
The successful research by ARI Pune highlights the efficacy of autonomous institutes under the DST in producing globally recognized breakthroughs in nanomedicine.
**Action Required**
The Department may consider further support or dissemination of these findings to promote national advancements in precision medicine.
Key Entities Referenced
Agharkar Research Institute (ARI), Pune: An autonomous research institute under the Department of Science and Technology that developed an innovative biodegradable nanocarrier platform for breast cancer gene therapy.
Department of Science and Technology (DST): The central government department that provides administrative oversight and support to the Agharkar Research Institute for its scientific research initiatives.
Advanced Healthcare Materials: The scientific journal that published the research findings regarding targeted gene silencing and the development of next-generation nanomedicine.
Ministry of Science & Technology
Next-generation nanomedicine can silence key
cancer drivers
प्रव तथ: 03 JUN 2026 5:50PM by National
Scientists from Pune have reported a gene-silencing strategy that can drive effective tumor inhibition in
breast cancer, highlighting its potential as next-generation precision nanomedicine.
Advances in cancer nanomedicine are increasingly shifting toward precision strategies that directly silence
disease-driving genes while minimizing systemic toxicity.
Scientists from from the Agharkar Research Institute (ARI), Pune, an autonomous institute under the
Department of Science and Technology (DST), Government of India, have presemted an innovative
biodegradable nanocarrier platform engineered for targeted gene therapy in breast cancer.
The research, recently published in Advanced Healthcare Materials, provides new insights into targeted
gene silencing of key survival pathways in breast cancer, enabling efficient tumor targeting and
suppression, and offering a promising strategy for developing more effective and safer nanomedicine-
based therapies.
The system is built on biodegradable mesoporous silica nanoparticles—well known for their high loading
capacity and tunable surface chemistry—which enable efficient delivery of small interfering RNA
(siRNA) molecules. By functionalizing the nanocarrier with a protamine biopolymer and an MUC1-
specific aptamer, the researchers achieved precise tumor targeting, leveraging the overexpression of
MUC1 receptors on breast cancer cells. This targeting strategy significantly enhances cellular uptake
while reducing off-target effects, a key limitation in conventional therapies.Fig: MUC1-Targeted Silica Nanocarrier (MPPM) Engineered biodegradable mesoporous silica
nanohybrids target the MUC1 receptor overexpressed in breast cancer
A major highlight of the study by the team costsing of Niladri Haldar, Rajkumar Samanta, Surajit Patra,
Devyani Sengar, Sachin Jadhav, and Virendra Gajbhiye is the dual gene-silencing approach. The
nanocarrier simultaneously delivers siRNAs against two critical anti-apoptotic genes, MCL-1 and
Survivin—both known to promote tumor survival and resistance to therapy. Once inside the tumor
microenvironment, the glutathione-responsive design triggers controlled release of the therapeutic
payload, ensuring efficient intracellular delivery and activity.
Biological evaluations in MCF-7 breast cancer models demonstrated robust gene knockdown, resulting in
increased apoptosis and substantial tumor growth inhibition. Importantly, in vivo studies in Severe
Combined Immunodeficiency (SCID) mice showed that the nanocarrier accumulates effectively at tumor
sites and exhibits minimal systemic toxicity, as evidenced by favorable histological outcomes. These
findings align with growing evidence that aptamer-guided nanocarriers can significantly improve tumor
specificity and therapeutic efficacy.
Overall, this work highlights a powerful convergence of targeted delivery, stimuli-responsive release, and
combinatorial gene silencing. By integrating these features into a single biodegradable platform, the study
provides a compelling framework for next-generation RNAi-based cancer therapies. Such approaches
could play a critical role in advancing precision oncology, offering more effective and safer alternatives to
traditional chemotherapy.
The research was conducted by scientists from the Nanobioscience Group at the Agharkar Research
Institute, Pune, India.
Publication Link: https://advanced.onlinelibrary.wiley.com/doi/abs/10.1002/adhm.202505296?af=R
***
NKR/FT
(रलीज़ आईडी: 2268513) आगंतुक पटल : 841
इस वज्ञ को इन भाषाओ ंम पढ़: Urdu , ही , Marathi , Tamil